InvestorsHub Logo
Followers 14
Posts 817
Boards Moderated 0
Alias Born 02/24/2010

Re: None

Thursday, 07/03/2014 2:51:33 AM

Thursday, July 03, 2014 2:51:33 AM

Post# of 403754
LOL, some of you are trying to pull this down before what should be the biggest catalyst of the companies history to date...a interim report on B. If there is no significant difference between arms we might actually get some numbers.

The K trial is going swimmingly. I posted this last month and will so again..Harvard would not take this K trial to cohort 8 if there was nothing there. They surely wouldn't put patients stage 4 terminally ill patients with no other treatment options through all that nor waste their own time on it. K already passed its interim report. Look at all these patients that have done multiple cycles..what for the fun of it?

Their is no leaks because this is Harvard and patients that have had their terminal cancer stabilized by Kevetrin are not going to do anything to jeopardize their treatment. This includes informing share holders of their wonderful success story.

The trials length is its success and Leo shouldn't say much until the trial is over. If he was actually giving many of the details so many want I would be nervous that he is covering something up. This is just how clinical trials go....IMO Leo's silence is golden